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 Augmentation Treatment with Amisulpride in 
Schizophrenic Patients Partially Responsive to 
Olanzapine 
 Nonetheless, rigorous data on combination ther-
apy in schizophrenia are rare and further rand-
omized controlled trials, naturalistic trials and 
head-to-head-trials are necessary  [25] . Treat-
ment-emergent positive and / or negative symp-
toms under clozapine monotherapy might benefi t 
from adding a second atypical substance. Data 
that do exist refer mostly to combinations of 
clozapine and another antipsychotic in clozap-
ine-resistant schizophrenia, where we can fi nd 
some meta-analysis  [26 – 29] . On the other hand, 
however, in their fi nal recommendations the 
National Association of State Mental Health Pro-
gram Directors (NASMHPD)  [30] acknowledges 
that double-blind, randomized clinical trials 
present insurmountable methodological limita-
tions to evaluate the eff ectiveness of psychotropic 
drug combinations and suggest that naturalistic 
studies be used and accepted as the mechanism 
by which to identify optimal combinations of 
antipsychotics. In this sense, there is a previous 
paper in our setting that retrospectively reviews 
the use of AP in discharge reports of schizophre-
 Introduction 
 ▼ 
 Antipsychotic polypharmacy (AP) for the treat-
ment of psychosis is a more widespread thera-
peutic recourse in clinical practice  [1 – 18] than 
might be expected, despite the paucity of data to 
support it  [19] and the consensus statements 
considering monotherapy as the standard treat-
ment for schizophrenia  [20 – 24] . In a study con-
ducted in Japan  [18] , 90  % of patients with 
schizophrenia were being treated with AP, con-
sisting mainly of fi rst-generation antipsychotic 
drugs, one with high potency and the other a low 
potency agent. Although this practice varies by as 
much as 17  % in non-hospitalized patients in the 
United States of America  [9] , it is of interest to 
point out that there are studies indicating that AP 
is a growing phenomenon  [11,  12] . Also in the 
United States, in a naturalistic study of AP with 
atypical antipsychotics for the treatment of 
schizophrenia, Faries et  al.  [17] observed that 
almost 60  % of schizophrenic patients received AP 
for an average of 156 out of 165 days. 
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 Abstract 
 ▼ 
 Objective:  The association of antipsychotics 
is a widespread therapeutic resource in clinical 
practice. The purpose of the present work was to 
evaluate the effi  cacy and safety of amisulpride 
augmentation in patients responding at least 
partially to olanzapine. 
 Methods:  In this observational 3-months 
open-label investigation, we evaluated the eff ec-
tiveness of the addition of amisulpride to 49 
subjects, after having scored at least 25 on the 
 brief psychiatric rating scale (BPRS) following 
olanzapine monotherapy for 6 weeks. Patients 
were assessed at baseline, 1 and 3 months using 
the BPRS, the  clinical global impression severity of 
illness (CGI-S) scale and the  Udvalg for Kliniske 
Undersogelser side eff ect rating scale (UKU). 
 Results:  In subjects who were at least partially 
responsive to monotherapy with olanzapine, 
coadjuvant treatment with amisulpride achieved 
a statistically signifi cant improvement in mental 
status over a 3 month period as measured by 
the BPRS, CGI and UKU scales. The response rate 
(  >  20  % reduction in BPRS score) was 75.51  % . 
 Conclusions:  Amisulpride augmentation, in a 
group of patients partially or non-responsive 
to olanzapine, may lead to an improvement in 
schizoprenic symptoms. However, these results 
are subject to several limitations making it dif-
fi cult to derive fi rm clinical recommendations, 
and underscoring the need for future research 
into the value of these therapeutic alternatives 
in poor responders. 
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nia patients over a 1-year period at a brief hospitalization unit 
 [31] with the aim of assessing standard clinical practice. This 
paper reported that 55.5  % of patients received AP at the time of 
discharge and the coadjuvant antipsychotic drug most com-
monly used was amisulpride. It subsequently analyzed the 
cohort of patients in whom this strategy was used  [32] and, in 
the authors ’ opinion, there are 2 groups of patients with schizo-
phrenia who might benefi t from using AP with amisulpride as 
the treatment strategy of choice. The fi rst group comprised 
patients presenting a partial response to clozapine and the sec-
ond, patients who generally required hospitalization, with acute 
psychotic processes, and who presented associated behavioral 
disorders, particularly aggressiveness. In both cases, however, it 
was advisable to resume monotherapy once the patients ’ clinical 
situation had been stabilized  [20] . 
 Amisulpride is an antipsychotic that has been widely used in 
Europe since 1988, although it has yet to be marketed in the 
United States or Canada. We believe it would meet the require-
ments for augmentation therapy  [33] from the perspective of 
rational AP. In vitro, amisulpride has high selectivity for D 2 / D 3 
dopamine receptors and little or no affi  nity for D 1 , D 4 , or D 5 
receptors, as well as exhibiting little or no affi  nity for muscarinic, 
histaminic, or adrenergic receptors  [34] . Amisulpride acts pref-
erentially in the limbic system, increasing cortical dopaminergic 
transmission and inhibiting limbic transmission. Amisulpride 
remains practically unmetabolized and is excreted largely 
unchanged in urine and feces  [34,  35] . These pharmacological 
characteristics make it an adjuvant agent of special interest. 
 Although little information is available at this time  [36 – 39] , we 
believe amisulpride ’ s characteristic receptor profi le may boost 
olanzapine ’ s wide receptor profi le and its moderate ability to 
block D 2 . In 2004, Zink et  al.  [36] published the fi rst retrospec-
tive series consisting of 7 cases of treatment-resistant schizo-
phrenic patients who responded to the combination of 
olanzapine and amisulpride. The goal of this work is to test the 
hypothesis that amisulpride augmentation would be well toler-
ated and improve the mental status of patients who fail to 
respond or only partially respond to olanzapine, one of the 2 
most widely prescribed atypical antipsychotics in our setting, by 
means of an observational analysis of cases. 
 Patients and Methods 
 ▼ 
 Design and subjects 
 This is a naturalistic, retrospective and multicenter narrative 
case series of a sample of treatment-resistant schizophrenic 
patients followed at a psychiatric out-patient clinic. This study 
contemplates a subsample of the patients participating in a 
larger study reviewing the psychotropic drugs prescribed to 
patients. The review method consisted of systematically exam-
ining the clinical data recorded of all patients attended by 10 
psychiatrists for a period of 12 months to obtain uniform infor-
mation about the entire sample. After agreement from the treat-
ing psychiatrists, potential subjects were approached and 
informed written consent to participate was obtained. Patient 
data with a minimum olanzapine treatment duration of 6 weeks 
were analyzed to ensure that there had been a reasonable time 
period during which to observe responses. All patients were 
over 18 years of age and met DSM-IV criteria for schizophrenia 
and none of them were under amisulpride or olanzapine before. 
Individuals meeting DSM-IV criteria proposed for investigation 
of post-psychotic depression and with a history of substance 
dependence were excluded. Following Munro et  al.  [40] , those 
patients scoring at least 25 on the  brief psychiatric rating scale 
(BPRS 0 – 6)  [41] were classifi ed as non-responders or partial 
responders. 
 Participants began coadjuvant treatment with amisulpride at 
the discretion of their psychiatrist following his or her standard 
clinical practice. Olanzapine doses were modifi ed according to 
the treating psychiatrists ’ clinical judgment. The same assess-
ment scales were used at follow-up as at baseline and were 
administered at 1 and 3 months of initiating amisulpride. 
 The response criteria consisted of a reduction on the BPRS score 
at follow-up of greater than 20  % vs. baseline and a fi nal  clinical 
global impression severity of illness (CGI-S)  [42] scale score of 3 or 
less; extrapyramidal eff ects were measured using the  Udvalg for 
Kliniske Undersogelser side eff ect rating scale (UKU)  [43] . The 
complete review of clinical data included, when possible, sub-
jects who discontinued amisulpride and the reasons for treat-
ment discontinuation were recorded. Finally, these patients 
were grouped together and the initial epidemiological charac-
teristics were compared with patients who maintained treat-
ment after 3 months. 
 Clinical ratings and statistical analysis 
 Demographic and clinical data included age, gender, weight and 
height, history of schizophrenia, and number of hospital admis-
sions due to acute schizophrenic episodes. Other information 
recorded included olanzapine dose and concomitant psycho-
tropic medication (benzodiazepines, antidepressants, anticon-
vulsants, and biperidene) (  ● ▶  Table  1 ). 
 The BPRS was administered to determine both the presence and 
severity of positive and negative symptoms of schizophrenia; 
the CGI-S scale was used to assess disease severity from the 
 clinicians ’ perspective, and the UKU was applied to detect any 
change in the extrapyramidal side-eff ect profi le following 
 augmentation. 
 Data for each psychometric scale score were analyzed by 
repeated measure analysis of variance (ANOVA-RM). The intra-
subject term was the individual patient score and the repeated 
 Table 1  Baseline demographic and clinical data of total population (n  =  49). 
 Data   Mean / Frequency /
 Percentage / Range 
 age, mean   35.60 (SD 8.95) 
range 18 – 60 
 gender  male  36 (73.47  % ) 
  female  13 (26.53  % ) 
 weight   78.77 (SD 12.014) 
 height (cm)   171.83 (SD 7.39) 
 BMI   26.68 (SD 3.69) 
 diagnosis  paranoid S  32 (65.31  % ) 
  residual S  6 (12.24  % ) 
  undiff erentiated S  8 (16.33  % ) 
  disorganized S  3 (6.08  % ) 
 in / out patient status at baseline  
  out-patient  35 (71.43  % ) 
  in-patient  14 (28.57  % ) 
 olanzapine doses, 
mean (mg / day) 
  16.99 (SD 7.16), 
range 5 – 30 
 concomitant psychotropic medication  
  BZD  22 (44.90  % ) 
  antidepressants  10 (20.41  % ) 
  anticonvulsants  5 (10.20  % ) 
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term was the time-point (baseline, 1 and 3 months). Compari-
son between baseline epidemiological data and diff erences in 
psychometric scores, from subjects who discontinued amisul-
pride vs. those who maintained amisulpride were analyzed 
using Student ’ s t-test. As well as, categorical variables were ana-
lyzed by the chi-squared ( χ 2 ) test or McNemar ’ s test (if related). 




 49 subjects received augmentation with amisulpride; of these, 
41 (83.67  % ) were under the same treatment and 2 (4.08  % ) dis-
continued amisulpride before the fi rst month. There were no 
associations between any of the sociodemographic characteris-
tics and the baseline clinical variables. Data of the initial 49 
patients are shown in   ● ▶  Table  1 (for intention-to-treat). 
 In partial or non-responders to olanzapine in monotherapy, 
coadjuvant treatment with amisulpride achieved a statistically 
signifi cant improvement in subjects ’ mental status as measured 
by the BPRS and CGI scales over a 3-month period (  ● ▶  Table  2 ). 
All measures showed signifi cant improvement and the improve-
ment from 0 – 1 month was equivalent to that observed after the 
1- to 3-month interval. 
 Using the defi ned criteria (  >  20  % reduction in BPRS score), 37 
(90.24  % ) of the 41 subjects completing the 3-months responded 
to co-administration of amisulpride (  ● ▶  Table  3 ). This repre-
sented a response rate of 75.51  % of the total cohort of 49 sub-
jects, including those who were discontinued. 33 subjects 
(67.35  % of the total cohort) responded as per the CGI, as defi ned 
by a score of 3 or less. 
 Amisulpride doses were lowest at the start and underwent no 
major changes following the dose increase at visit 2. There was a 
signifi cant, progressive decrease in the olanzapine dosage which 
was maintained throughout the time. Olanzapine doses reached 
their lowest at the fi nal visit. Sequential data for every visit are 
shown in   ● ▶  Table  2 , per protocol-analysis (n  =  41). 
 The mean age was 35.61 (SD 8.86, range 18 – 60) years, and the 
mean number of prior hospitalizations was 2.21 (SD 2.97, range 
0 – 13). 6 patients were using a second neuroleptic prior to the 
addition of amisulpride (aripiprazol, quetiapine, haloperidol, 
fl uphenazine, risperidone, extended release risperidone; one 
each) and one patient was taking lithium. 7 patients (14.28  % ) 
were receiving treatment with anticholinergics (biperidene); 22 
(44.89  % ) were taking benzodiazepines (2 of them were on 2 dif-
ferent ones); 10 patients (20.41  % ) were on serotonin, norepine-
phrine, or dual reuptake inhibitor antidepressants, and 5 
(10.20  % ) were taking antiepileptics. After 3 months there were 
not statistically signifi cant diff erences in the patients who 
received other psychotropic drugs, although benzodiazepine ’ s 
average dose was lowered by 22.23  % throughout 3 months of 
follow-up. The CGI scores ranged from 5.20 (SD  =  0.98) at the 
start to 3.64 (SD  =  1.01) at the third visit ( Δ  =   −  1.56). The BPRS 
scores ranged from 32.38 (SD  =  5.63) on admission to 18.15 
(SD  =  6.53) at the third visit ( Δ  =   −  14.23). 
 Severity of extrapyramidal eff ects (UKU) at the start of treat-
ment displayed the following distribution: absent in 75.5  % of 
patients, mild in 14.3  % , and moderate in 10.2  % . By the third 
mouth, they were absent in 65.3  % , mild in 16.3  % , and moderate 
in 2  % . As regards the use of biperidene as a corrector: 3 patients 
were taking 4  mg at the fi rst visit; at the second visit, 1 was on 
3  mg and 2 were on 4  mg; at the third visit, 1 patient was taking 
2  mg, 3 patients were taking 3  mg, and 3 patients were on 4  mg. 
Although larger doses were used (and in more patients) at the 
end point, the diff erence does not achieve statistical signifi -
cance. 
 8 subjects (16.33  % ) failed to complete the 3 months of treat-
ment. 6 subjects discontinued treatment for reasons that were 
unclear; one, due to sedative eff ects, and the other because of a 
seizure that required hospitalization, during which the initial 
treatment was suspended. Most likely, the seizure had to be 
attributed to a hypoglycemic state due to a previously diagnosed 
diabetes mellitus. Finally, after 3 months, treatment was sus-
pended in a ninth patient due to weight gain and amenorrhea. 
 The demographic and baseline clinical characteristics diff ered 
signifi cantly between those subjects who maintained the 
 treatment after 3 months (n  =  41) and those who discontinued 
(n  =  8): initial CGI [5.87 (SD 0.83) vs. 5.07 (SD 0.96); Student ’ s 
t-test   −  2.20; p  =  0.03], and initial size value [177.00 (SD 5.34) 
vs. 170.74 (SD 7.35); Student ’ s t-test   −  2.28; p  =  0.03]; both 
parameters being lower in patients who discontinued treat-
ment. 
 As illustrated in   ● ▶  Fig.  1 and   ● ▶  Table  4 , the co-administration of 
amisulpride in neuroleptic-treated patients did not result in a 
corresponding increase in side eff ects over the 3-month period 
 Table 2  Clinical ratings and mean drug doses at baseline, 4 weeks, and 12 weeks of patients who maintained treatment (Pillai’s Trace and adjustment for 
multiple comparisons by Bonferroni). 
  Visit 1  Visit 2  Visit 3  F  p 
 olanzapine dose, mean (mg / day)  17.13 (SD 7.19) *  14.63 (SD 5.85) *  13.68 (SD 6.29) *  5.02  0.01 
 amisulpride dose, mean (mg / day)  536.58 (SD 238.49) *  626.83 (SD 271.13) *  602.44 (SD 285.03)  5.49  0.01 
 BPRS  32.19 (SD 5.65) *  22.98 (SD 6.69) *  18.15 (SD 6.53) *  92.46   <  0.01 
 CGI  5.05 (SD 0.97) *  4.25 (SD 1.04) *  3.64 (SD 1.01) *  26.87   <  0.01 
 UKU  0.32 (SD 0.65)  0.39 (SD 0.66)  0.24 (SD 0.49)  1.32  0.28 
 BPRS (brief psychiatric rating scale); CGI (clinical global impression); UKU (Udvalg for Kliniske Undersogelser side eff ect rating scale) 
 *  Values showing diff erences in Bonferroni’s multiple comparison adjustments 
 Table 3  Response rate of patients who maintained treatment, as per 
 percentage of improvement on BPRS and CGI. 
 Response 
rating 
 Number of patients responding 
to treatment (  % ) 
 Mean (  % ) improve-
ment at 3 months 
  1 month 
(n  =  47) 
 3 months 
(n  =  41) 
 
 BPRS  33 (70.21  % )  37 (90.24  % )  4.05, SD  =  6.53 
(12.58  % ) 
 GCI *  29 (59.18  % )  33 (67.35  % ) * *  21 (63.64  % ) 
 BPRS (brief psychiatric rating scale); CGI (clinical global impression) 
 *  At baseline, 12 patients (24.49  % ) already had a GCI score   ≤  3 
 * * 2 patients were lost for data tracking purposes 
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when all eff ects were analyzed globally (McNemar, p  >  0.05, 
repeated test with Bonferroni correction). 
 Discussion 
 ▼ 
 The main argument against the use of AP is the paucity of clini-
cal trials supporting this practice  [25 – 27] , as well as the sum of 
the possible side eff ects that would have to be taken into consid-
eration. It is true, too, that there is very poor evidence to cor-
roborate the combination of antipsychotic drugs in the treatment 
of schizophrenia, as the data available refer largely to combina-
tions of clozapine plus another antipsychotic in cases of clozap-
ine-resistant schizophrenia  [29] . On the other hand, the high 
frequency of AP in the studies reviewed, not only in hospital 
centers, but also in the out-patient setting  [1,  5,  6,  9 – 11,  13] , leads 
us to think that this treatment regime is chosen by clinicians as 
a treatment strategy for symptom control  [31,  32] even prior to 
resorting to clozapine and not only after patients have failed to 
respond suffi  ciently to clozapine treatment. This may often be 
the case given the diffi  culties entailed in managing this antipsy-
chotic in particular  [44] . 
 This work explores the hypothesis that the combination of ami-
sulpride plus olanzapine would lead to an improvement in the 
mental status of those patients who fail to respond suffi  ciently 
to treatment with olanzapine alone. Although its naturalistic 
design does not allow specifi c recommendations to be made, it 
refl ects the usual clinical practice in our setting and may be of 
use in identifying optimal combinations of antipsychotic drugs, 
in line with the recommendations put forth by NASMHPD  [30] . 
On the one hand, we start from the basis of a previous retrospec-
tive study in our setting that reveals that the most commonly 
chosen drug for coadjuvant treatment is amisulpride  [31,  32] . 
Olanzapine has been chosen by virtue of the fact that it is one of 
the 2 antipsychotic drugs most often prescribed for schizophre-
nia in our setting. 
 In 2004, Zink et  al.  [36] published a retrospective review of the 
case histories of their hospital, reporting the fi rst series of 7 
cases of schizophrenic patients discharged with a response to 
the combination of olanzapine and amisulpride. This paper sets 
out to test the hypothesis that amisulpride augmentation would 
improve the mental status of patients not responding or respond-
ing only partially to olanzapine in standard practice. 
 Unlike the Zink study, in which all 7 patients were in-patients, in 
this investigation, of the 49 patients (36 males and 13 females) 
treated with coadjuvant amisulpride and prior treatment with 
olanzapine, 35 had a baseline visit in an out-patient regime prior 
to initiating combined treatment and in 14 cases, the baseline 
visit took place at discharge from an in-patient facility. They 
were subsequently all followed as out-patients. 
 Our results are similar to those of Zink et  al.  [36] insofar as CGI 
and  global assessment of functioning (GAF) scores are concerned. 
However, the combination strategy in our case series is diff erent. 
The mean dose of olanzapine used in Zink ’ s series was 21.4  mg 
(range  =  5 – 40  mg) and the mean dose of amisulpride was 
485.7  mg (range  =  200 – 800  mg), whereas in our investigation at 
the third visit, patients were being treated with higher amisul-
pride doses (mean 617.50  mg, SD  =  271.64  mg, range  =  200 –
 1  200  mg) and lower doses of olanzapine (mean 13.68  mg, 
SD  =  6.29, range  =  0 – 30; in 2 patients olanzapine was even with-
drawn and amisulpride was left as monotherapy). In this sense, 
if we conduct a statistical analysis of responders, we fi nd a sta-
tistically signifi cant diff erence only between the 3 visits; none-
theless, it is worth noting that the initial amisulpride dose at 
visit 1 is lower in non-responders vs. responders [375.00 
(SD  =  171.22) vs. 551.35 (SD  =  246.78), Mann Whitney ’ s U 134.00, 






















Visit 1 Visit 2 Visit 3
 Fig. 1  Evolution of extrapyramidal symptoms 
(UKU modifi ed). 
 Table 4  Adverse eff ects. 
  Visit 1 *   %  Visit 2   %  Visit 3   % 
  n  =  49   n  =  47   n  =  41  
 absences  37  75.5  36  76.6  35  85.4 
 weight gain  7  14.3  6  12.8  4  9.8 
 drowsiness  4  8.2  0  –  0  – 
 altered libido  1  2.0  0  –  0  – 
 constipation  0  –  2  4.3  1  4.3 
 dizziness  0  –  2  4.3  1  4.3 
 eneuresis  0  –  1  2.1  0  – 
 *  The eff ects noted for the fi rst visit are those reported by the patients with the 
treatment prior to the start of amisulpride 
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 At the start of treatment, more than 3 quarters of the sample 
reported no extrapyramidal eff ects (UKU); 14.3  % reported mild, 
and 10.2  % reported moderate extrapyramidal symptoms (EPS). 
These percentages shifted to 65.3  % reporting no EPS, the rest 
stated that they were 16.3  % mild, and 2  % , moderate. While it is 
true that there were fewer patients with no EPS at visit 3, it is of 
particular interest to note the signifi cant decrease in those suf-
fering from moderate EPS at visit 3, as well as the fact that there 
were no patients reporting severe EPS at any of the study time 
points. 
 Although there is some evidence that metabolic side eff ects of 
clozapine and olanzapine might change in a dose-dependent 
manner we did not gain any further evidence in this direction. 
Treatment was suspended in a patient due to observed weight 
gain and amenorrhea that cannot be attributed to increased pro-
lactin and independent mechanisms must be assumed. 
 We believe that amisulpride ’ s effi  cacy in augmenting olanzapine 
can be attributed to the complementary receptor profi les of both 
drugs. The data suggest that the combination of olanzapine plus 
amisulpride may represent an appropriate treatment strategy 
for patients lacking suffi  cient response to treatment with olan-
zapine. The characteristic receptor profi le of amisulpride, with a 
highly selective blockade of D 2 / D 3 receptors  [34] , may boost the 
wide receptor profi le of olanzapine and its moderate D 2 -block-
ing ability. The selectivity shown by amisulpride for the limbic 
system translates into low rates of extrapyramidal eff ects; fur-
thermore, it allows lower doses of olanzapine to be used, thereby 
minimizing the risk of weight gain. From a pharmacokinetic 
standpoint, no interactions are to be expected between both 
antipsychotics, since amisulpride is excreted un-metabolized 
predominantly in urine, whereas olanzapine is metabolized by 
the CYP450 system. 
 Limitations 
 ▼ 
 Several limitations need to be considered when interpreting 
these results. These include: no assessments of serum levels 
(olanzapine and amisulpride), no urine drug screening, short 
minimal treatment period with olanzapine, lack of metabolic 
parameters (weight, BMI, fasting glucose, triglycerides or cho-
lesterol), lack of serum prolactin assessments. Furthermore, the 
olanzapine dose at baseline (mean 17  mg, range 5 – 30  mg) may 
have been insuffi  cient (less than 10  mg) in 2 patients (5  mg). 
Regarding olanzapine dose, smoking habits were not assessed. 
Smoking induces cytochrome isoform 1A2 that metabolizes 
olanzapine. 
 Despite these limitations, fi ndings are supported by observa-
tions derived from the largest investigation combining olanzap-
ine and amisulpride in the acute phase showing regular clinical 
practice. In this sense, the analyzed data extend to some aspects 
of the general clinical practice where antipsychotic cotreatment 
strategies seem to be predominantly utilized in patients who 
have not failed clozapine. In view of the prevalence of this clini-
cal practice and the paucity of evidence in its support, we con-
ducted a naturalistic observation following the standard clinical 
practice reported previously  [31,  32] . In our opinion studies 
combining non-clozapine second generation antipsychotics, uti-
lized most in clinical practice, are required. Such studies should 
also explore the merits of combining antipsychotics in the acute 
phase, instead of waiting until non-response has occurred, and 
last for at least 10 weeks  [45] . Furthermore, recent data, suggest-
ing that non-response at 1 – 4 weeks is highly predictive of future 
non-response  [46,  47] should also be taken into account when 
deciding at what time patients with an unsatisfactory response 
should be considered in standard clinical practice to antipsy-
chotic combinations vs. continued monotherapy. 
 In summary, these data suggest that, at least in poor responders, 
olanzapine augmentation with amisulpride may be superior to 
antipsychotic monotherapy. The results from this work are 
insuffi  cient to derive conclusive clinical recommendations. 
Rather, it provides information regarding the need for specifi c 
studies and highlights methodological considerations that 
should guide the design of future studies. It opens up a line for 
conducting further research into the value of these therapeutic 
alternatives in poor responders to other treatment schemes, 
according to several authors referring to the need for eff ective-
ness, naturalistic or real life studies designed to shed light on the 
antipsychotics that should be preferred in normal clinical prac-
tice to treat schizophrenia and poor responders to treatments 
 [48,  49] . 
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